BUZZ-Biohaven rises after completing enrollment in mid-stage obesity drug trial

Reuters03-19
BUZZ-Biohaven rises after completing enrollment in mid-stage obesity drug trial

** Shares of drugmaker Biohaven BHVN.N rise 2% to $9.26 premarket

** Co says it finished enrolling patients in a mid-stage trial for experimental obesity drug, taldefgrobep alfa,

** Expects trial results in second-half of 2026

** Says the injectable drug is being tested as a standalone treatment, given weekly or monthly, on overweight and obese adults

** Adds the study will track changes in weight, fat and muscle mass over 24 weeks, followed by a 24-week extension to see if changes to weight and body-composition sustain or improve over a longer period

** Earlier studies showed the experimental drug helped reduce fat, while preserving or increasing muscle with side effects similar to placebo

** Shares fell ~70% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment